BioXcel Therapeutics, Inc. (BTAI)
Confidential investigation: officers & directors’ potential breach of fiduciary duties to investors.
Investigation
05/17/2022
Initial Lawsuit
06/06/2022
Lawsuit Progression
08/05/2022
Investors investigation in connection with Digital Turbine, Inc.’s internal controls over financial reporting and restatement of its financials for the periods ended June 30, 2021, September 30, 2021, and December 31, 2021.
This post is open for investors to gather facts, and findings and track their exposure to related lawsuits. We invite investors and shareholders to contribute to this investigation for their own benefit, add events to the factual timeline below and vote on events’ pertinence.
A lawsuit was subsequently filed. We will update this post as it unfolds.
05/17/2022
Digital Turbine announces that its Form 10-Q filed with the U.S. Securities and Exchange Commission (SEC) on August 9, 2021, November 2, 2021, and February 8, 2022, should no longer be relied upon. The company also reveals its expected net revenues, substantially lower than previously reported “gross” revenues.
“In connection with the integration of the Company’s recently acquired businesses (AdColony Holding AS and Fyber N.V. (the “Acquired Companies”)), management performed a review of the presentation of revenues and license fees and revenue share based on the accounting guidance for revenue recognition, including considerations of principal and agent (or “gross and net”) presentation. After a detailed review of the Acquired Companies product lines and related contracts with customers and publishers, the Company concluded that each Acquired Company acts as an agent in certain of their respective product lines and, as a result, the revenues for those product lines should be reported net of license fees and revenue share. Previously, all revenues of the Acquired Companies, which are reported as separate segments referred to as In App Media – AdColony and In App Media – Fyber, respectively, were reported on a gross basis.”
“Previously, the Company’s revenues were reported as approximately $212.6 million for the three-month period ended June 30, 2021, $310.2 million for the three-month period ended September 30, 2021, and $375.5 million for the three-month period ended December 31, 2021. Based on its preliminary assessment, the Company expects that revenue on a net basis will be reported as approximately $158.1 million for the three-month period ended June 30, 2021, $188.6 million for the three-month period ended September 30, 2021, and $216.8 million for the three-month period ended December 31, 2021.”
Stock Impact
Close | Previous close | Price variation | Percentage variation |
---|---|---|---|
$25.28 | $27.21 | $-1.93 | -7.09% |
A shareholder filed this securities class action on behalf of persons and entities that purchased or otherwise acquired Digital Turbine securities between August 9, 2021, and May 17, 2022, inclusive.
According to the complaint, defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the company’s business, operations, and prospects. Specifically, defendants allegedly failed to disclose to investors:
(1) that the company’s recent acquisitions, AdColony and Fyber, act as agents in certain of their respective product lines;
(2) that, as a result, revenues for those product lines must be reported net of license fees and revenue share, rather than on a gross basis;
(3) that the company’s internal control over financial reporting as to revenue recognition was deficient; and
(4) that, as a result of the foregoing, the company’s net revenues were overstated throughout fiscal 2022; and
(5) that, as a result of the foregoing, defendants’ positive statements about the company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis.
The lead plaintiff deadline has passed, we will update this page as the lawsuit progresses
Confidential investigation: officers & directors’ potential breach of fiduciary duties to investors.
Whether directors and officers of Kewaunee Scientific Corporation (KEQU) breached their fiduciary duties to the company and its shareholders.
Whether directors and officers of Builders FirstSource, Inc. (BLDR) breached their fiduciary duties to the company and its shareholders.
Whether directors and officers of Amicus Therapeutics, Inc. (FOLD) breached their fiduciary duties to the company and its shareholders.
Whether directors and officers of LegalZoom.com, Inc. (LZ) breached their fiduciary duties to the company and its shareholders.
Whether directors and officers of Inari Medical, Inc. (NARI) breached their fiduciary duties to the company and its shareholders.